Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Matinas BioPharma announces DSMB approval of first cohort in EnACT study » 06:33
10/19/20
10/19
06:33
10/19/20
06:33
MTNB

Matinas BioPharma

$0.89 /

+0.0223 (+2.56%)

Matinas BioPharma…

Matinas BioPharma Holdings announced that the independent Data and Safety Monitoring Board, or DSMB, of the EnACT study, or Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial, has completed a pre-specified review of the first cohort and unanimously recommended progression to the second cohort of patients. Enrollment in this next randomized EnACT cohort, with 40 active-treatment patients, is expected to begin shortly, with the next DSMB evaluation of safety and efficacy data anticipated to occur in the middle of 2021.

ShowHide Related Items >><<
MTNB Matinas BioPharma
$0.89 /

+0.0223 (+2.56%)

MTNB Matinas BioPharma
$0.89 /

+0.0223 (+2.56%)

08/25/20 Piper Sandler
Matinas BioPharma transferred with an Overweight at Piper Sandler
03/31/20 Piper Sandler
Matinas BioPharma price target lowered to $1.50 from $3.00 at Piper Sandler
01/27/20
Fly Intel: Top five analyst initiations
01/26/20 Piper Sandler
Matinas BioPharma initiated with an Overweight at Piper Sandler
MTNB Matinas BioPharma
$0.89 /

+0.0223 (+2.56%)

  • 10
    Jan
Conference/Events
Matinas BioPharma management to meet virtually with BTIG » 07:52
10/02/20
10/02
07:52
10/02/20
07:52
MTNB

Matinas BioPharma

$0.76 /

-0.0041 (-0.53%)

Virtual Meeting to be…

Virtual Meeting to be held on October 2 hosted by BTIG.

ShowHide Related Items >><<
MTNB Matinas BioPharma
$0.76 /

-0.0041 (-0.53%)

MTNB Matinas BioPharma
$0.76 /

-0.0041 (-0.53%)

08/25/20 Piper Sandler
Matinas BioPharma transferred with an Overweight at Piper Sandler
03/31/20 Piper Sandler
Matinas BioPharma price target lowered to $1.50 from $3.00 at Piper Sandler
01/27/20
Fly Intel: Top five analyst initiations
01/26/20 Piper Sandler
Matinas BioPharma initiated with an Overweight at Piper Sandler
MTNB Matinas BioPharma
$0.76 /

-0.0041 (-0.53%)

  • 10
    Jan
Over a month ago
Conference/Events
Maxim Group and M-Vest to co-host a virtual conference » 08:12
09/17/20
09/17
08:12
09/17/20
08:12
APLI

Applied Precision

$0.00 /

+ (+0.00%)

, CDTX

Cidara Therapeutics

$3.25 /

-0.01 (-0.31%)

, MTNB

Matinas BioPharma

$0.78 /

+0.005 (+0.65%)

, SCYX

Scynexis

$5.28 /

+0.11 (+2.13%)

, TFFP

TFF Pharmaceuticals

$15.18 /

+0.28 (+1.88%)

A Too Quiet…

A Too Quiet Pandemic--Fungal Disease Virtual Conference will be held on September 17.

ShowHide Related Items >><<
TFFP TFF Pharmaceuticals
$15.18 /

+0.28 (+1.88%)

SCYX Scynexis
$5.28 /

+0.11 (+2.13%)

MTNB Matinas BioPharma
$0.78 /

+0.005 (+0.65%)

CDTX Cidara Therapeutics
$3.25 /

-0.01 (-0.31%)

APLI Applied Precision
$0.00 /

+ (+0.00%)

03/10/20 Maxim
Applied Precision initiated with a Buy at Maxim
CDTX Cidara Therapeutics
$3.25 /

-0.01 (-0.31%)

03/10/20 Maxim
Cidara Therapeutics initiated with a Buy at Maxim
03/10/20 Maxim
Cidara Therapeutics initiated with a Buy at Maxim
01/27/20 Cantor Fitzgerald
Street underappreciates Cidara's Cloudbreak AVCs, says Cantor Fitzgerald
12/04/19 WBB Securities
Cidara Therapeutics upgraded to Buy from Speculative Buy at WBB Securities
MTNB Matinas BioPharma
$0.78 /

+0.005 (+0.65%)

08/25/20 Piper Sandler
Matinas BioPharma transferred with an Overweight at Piper Sandler
03/31/20 Piper Sandler
Matinas BioPharma price target lowered to $1.50 from $3.00 at Piper Sandler
01/27/20
Fly Intel: Top five analyst initiations
01/26/20 Piper Sandler
Matinas BioPharma initiated with an Overweight at Piper Sandler
SCYX Scynexis
$5.28 /

+0.11 (+2.13%)

TFFP TFF Pharmaceuticals
$15.18 /

+0.28 (+1.88%)

08/17/20 Maxim
TFF Pharmaceuticals price target raised to $18 from $12 at Maxim
08/14/20 Roth Capital
TFF Pharmaceuticals price target raised to $18 from $15 at Roth Capital
07/08/20 Maxim
TFF Pharmaceuticals initiated with a Buy at Maxim
02/27/20 Roth Capital
TFF Pharmaceuticals initiated with a Buy at Roth Capital
TFFP TFF Pharmaceuticals
$15.18 /

+0.28 (+1.88%)

SCYX Scynexis
$5.28 /

+0.11 (+2.13%)

MTNB Matinas BioPharma
$0.78 /

+0.005 (+0.65%)

CDTX Cidara Therapeutics
$3.25 /

-0.01 (-0.31%)

  • 10
    Jan
  • 10
    Dec
TFFP TFF Pharmaceuticals
$15.18 /

+0.28 (+1.88%)

MTNB Matinas BioPharma
$0.78 /

+0.005 (+0.65%)

TFFP TFF Pharmaceuticals
$15.18 /

+0.28 (+1.88%)

Hot Stocks
Matinas, FDA 'aligned' on next steps for MAT9001's Phase 3 development program » 07:02
09/15/20
09/15
07:02
09/15/20
07:02
MTNB

Matinas BioPharma

$0.72 /

+0.0227 (+3.27%)

Matinas BioPharma…

Matinas BioPharma announced the result of its End of Phase 2 Meeting with the U.S. Food and Drug Administration concerning the development and registration pathway for MAT9001, a potential best-in-class prescription omega-3 therapy. The official minutes of the meeting confirmed that the FDA and Matinas are aligned on key next steps for MAT9001's Phase 3 development program and registration pathway for an initial indication to treat severe hypertriglyceridemia, a clinical disorder associated with major complications such as pancreatitis and atherosclerotic cardiovascular disease. The Company remains on track to initiate its Phase 3 program in the first half of 2021. The Company and the FDA agreed on key elements of the Phase 3 program to support a New Drug Application filing, including the requirement for a single 12-week study to support efficacy in SHTG. Moreover, FDA provided flexibility to Matinas in the totality of patient safety data needed to meet regulatory requirements for NDA submission. The Company is evaluating several ways to both meet these requirements and to potentially provide additional data differentiating MAT9001 from other prescription omega-3 drugs.

ShowHide Related Items >><<
MTNB Matinas BioPharma
$0.72 /

+0.0227 (+3.27%)

MTNB Matinas BioPharma
$0.72 /

+0.0227 (+3.27%)

08/25/20 Piper Sandler
Matinas BioPharma transferred with an Overweight at Piper Sandler
03/31/20 Piper Sandler
Matinas BioPharma price target lowered to $1.50 from $3.00 at Piper Sandler
01/27/20
Fly Intel: Top five analyst initiations
01/26/20 Piper Sandler
Matinas BioPharma initiated with an Overweight at Piper Sandler
MTNB Matinas BioPharma
$0.72 /

+0.0227 (+3.27%)

  • 10
    Jan
MTNB Matinas BioPharma
$0.72 /

+0.0227 (+3.27%)

Hot Stocks
Matinas BioPharma appoints Natasha Giordano to board of directors » 07:43
09/14/20
09/14
07:43
09/14/20
07:43
MTNB

Matinas BioPharma

$0.69 /

+0.0247 (+3.69%)

, PLXP

PLx Pharma

$3.50 /

-0.13 (-3.58%)

Matinas BioPharma (MTNB)…

Matinas BioPharma (MTNB) announced the appointment of Natasha Giordano to its Board of Directors as an independent director and a member of the audit committee, effective Monday, September 14, 2020. She has served as President, CEO, and a director of PLx Pharma (PLXP) since January 2016. The Company also announced that Adam Stern will not stand for re-election to the Company's Board of Directors at the Company's Annual Meeting of Stockholders on November 2, 2020, instead transitioning to a consulting role where he will be available to the CEO and the Board of Directors on matters related to overall corporate and financial strategy.

ShowHide Related Items >><<
MTNB Matinas BioPharma
$0.69 /

+0.0247 (+3.69%)

MTNB Matinas BioPharma
$0.69 /

+0.0247 (+3.69%)

08/25/20 Piper Sandler
Matinas BioPharma transferred with an Overweight at Piper Sandler
03/31/20 Piper Sandler
Matinas BioPharma price target lowered to $1.50 from $3.00 at Piper Sandler
01/27/20
Fly Intel: Top five analyst initiations
01/26/20 Piper Sandler
Matinas BioPharma initiated with an Overweight at Piper Sandler
PLXP PLx Pharma
$3.50 /

-0.13 (-3.58%)

05/18/20 JMP Securities
PLx Pharma resumed with an Outperform at JMP Securities
PLXP PLx Pharma
$3.50 /

-0.13 (-3.58%)

MTNB Matinas BioPharma
$0.69 /

+0.0247 (+3.69%)

  • 10
    Jan
MTNB Matinas BioPharma
$0.69 /

+0.0247 (+3.69%)

Hot Stocks
Matinas BioPharma completes enrollment in ENHANCE-IT study » 16:28
08/27/20
08/27
16:28
08/27/20
16:28
MTNB

Matinas BioPharma

$0.78 /

-0.0271 (-3.36%)

Matinas BioPharma…

Matinas BioPharma announced that it has completed enrollment in the ENHANCE-IT study, a second head-to-head comparative study of MAT9001 against Vascepa. The ENHANCE-IT study is assessing MAT9001's effectiveness in reducing triglyceride levels and other important lipid markers, as well as characterizing bioavailability and blood levels of eicosapentaenoic acid and other omega-3 fatty acids. The company expects to have topline data available in the first quarter of 2021.

ShowHide Related Items >><<
MTNB Matinas BioPharma
$0.78 /

-0.0271 (-3.36%)

MTNB Matinas BioPharma
$0.78 /

-0.0271 (-3.36%)

08/25/20 Piper Sandler
Matinas BioPharma transferred with an Overweight at Piper Sandler
03/31/20 Piper Sandler
Matinas BioPharma price target lowered to $1.50 from $3.00 at Piper Sandler
01/27/20
Fly Intel: Top five analyst initiations
01/26/20 Piper Sandler
Matinas BioPharma initiated with an Overweight at Piper Sandler
MTNB Matinas BioPharma
$0.78 /

-0.0271 (-3.36%)

  • 10
    Jan
MTNB Matinas BioPharma
$0.78 /

-0.0271 (-3.36%)

Recommendations
Matinas BioPharma transferred with an Overweight at Piper Sandler » 16:14
08/25/20
08/25
16:14
08/25/20
16:14
MTNB

Matinas BioPharma

$0.82 /

+0.0176 (+2.20%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi took over coverage of Matinas BioPharma and kept an Overweight rating on the shares with a price target of $1.80, up from $1.50, which represents 126% potential upside. The company is "leading the path forward" in development of highly purified, prescription-only omega-3 free fatty acid drug, MAT9001, for treatment of cardiovascular and metabolic conditions, Rahimi tells investors in a research note.

ShowHide Related Items >><<
MTNB Matinas BioPharma
$0.82 /

+0.0176 (+2.20%)

MTNB Matinas BioPharma
$0.82 /

+0.0176 (+2.20%)

03/31/20 Piper Sandler
Matinas BioPharma price target lowered to $1.50 from $3.00 at Piper Sandler
01/27/20
Fly Intel: Top five analyst initiations
01/26/20 Piper Sandler
Matinas BioPharma initiated with an Overweight at Piper Sandler
01/24/20
Fly Intel: Top five analyst initiations
MTNB Matinas BioPharma
$0.82 /

+0.0176 (+2.20%)

  • 10
    Jan
MTNB Matinas BioPharma
$0.82 /

+0.0176 (+2.20%)

Hot Stocks
Matinas announces publication of results from Phase 1 portion of EnACT study » 07:07
08/20/20
08/20
07:07
08/20/20
07:07
MTNB

Matinas BioPharma

$0.82 /

-0.0035 (-0.43%)

Matinas BioPharma…

Matinas BioPharma Holdings announced the publication of data from the Phase 1 portion of the EnACT study for MAT2203, a novel oral formulation of amphotericin B, investigating its safety and tolerability. The data were published online in Antimicrobial Agents and Chemotherapy, a journal of the American Society of Microbiology, in a manuscript entitled "Safety and tolerability of a novel oral formulation of amphotericin B: Phase I EnACT trial". In the published manuscript, trial investigators reported results from the Phase 1A and 1B portions of the study. They concluded that MAT2203 was well tolerated when given in 4-6 divided daily doses without the toxicities commonly seen with IV amphotericin B. EnACT is a Phase 2 open-label, sequential cohort study of approximately 100 patients, financially supported by the National Institutes of Health, utilizing the Company's LNC platform delivery technology to orally deliver the traditionally IV-only fungicidal drug, amphotericin B. This study is a prospective, randomized trial evaluating the safety, tolerability and efficacy of MAT2203 in HIV-infected patients with cryptococcal meningitis, compared to treatment with standard IV-administered amphotericin B as induction therapy, and then followed by maintenance treatment with MAT2203. As previously reported, the U.S. Food and Drug Administration has designated MAT2203 as a Qualified Infectious Disease Product with Fast Track status for four indications, specifically, the prevention of invasive fungal infections due to immunosuppressive therapy, and the treatment of invasive candidiasis, invasive aspergillus and cryptococcal meningitis. In addition, the FDA has granted orphan drug designation to MAT2203 for the treatment of cryptococcosis.

ShowHide Related Items >><<
MTNB Matinas BioPharma
$0.82 /

-0.0035 (-0.43%)

MTNB Matinas BioPharma
$0.82 /

-0.0035 (-0.43%)

03/31/20 Piper Sandler
Matinas BioPharma price target lowered to $1.50 from $3.00 at Piper Sandler
01/27/20
Fly Intel: Top five analyst initiations
01/26/20 Piper Sandler
Matinas BioPharma initiated with an Overweight at Piper Sandler
01/24/20
Fly Intel: Top five analyst initiations
MTNB Matinas BioPharma
$0.82 /

-0.0035 (-0.43%)

  • 10
    Jan
MTNB Matinas BioPharma
$0.82 /

-0.0035 (-0.43%)

Earnings
Matinas BioPharma sees cash on hand sufficient to fund operations into 2023 » 16:16
08/10/20
08/10
16:16
08/10/20
16:16
MTNB

Matinas BioPharma

$0.93 /

+0.0419 (+4.72%)

Based on current…

Based on current projections, the company continues to believe that cash on hand is sufficient to fund operations into the first half of 2023.

ShowHide Related Items >><<
MTNB Matinas BioPharma
$0.93 /

+0.0419 (+4.72%)

MTNB Matinas BioPharma
$0.93 /

+0.0419 (+4.72%)

03/31/20 Piper Sandler
Matinas BioPharma price target lowered to $1.50 from $3.00 at Piper Sandler
01/27/20
Fly Intel: Top five analyst initiations
01/26/20 Piper Sandler
Matinas BioPharma initiated with an Overweight at Piper Sandler
01/24/20
Fly Intel: Top five analyst initiations
MTNB Matinas BioPharma
$0.93 /

+0.0419 (+4.72%)

  • 10
    Jan
MTNB Matinas BioPharma
$0.93 /

+0.0419 (+4.72%)

Earnings
Matinas BioPharma reports Q2 EPS (3c), consensus (3c) » 16:15
08/10/20
08/10
16:15
08/10/20
16:15
MTNB

Matinas BioPharma

$0.93 /

+0.0419 (+4.72%)

Cash, cash equivalents…

Cash, cash equivalents and marketable securities at June 30, 2020 were approximately $68.0M, compared to $27.8M at December 31, 2019.

ShowHide Related Items >><<
MTNB Matinas BioPharma
$0.93 /

+0.0419 (+4.72%)

MTNB Matinas BioPharma
$0.93 /

+0.0419 (+4.72%)

03/31/20 Piper Sandler
Matinas BioPharma price target lowered to $1.50 from $3.00 at Piper Sandler
01/27/20
Fly Intel: Top five analyst initiations
01/26/20 Piper Sandler
Matinas BioPharma initiated with an Overweight at Piper Sandler
01/24/20
Fly Intel: Top five analyst initiations
MTNB Matinas BioPharma
$0.93 /

+0.0419 (+4.72%)

  • 10
    Jan
MTNB Matinas BioPharma
$0.93 /

+0.0419 (+4.72%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.